WO2016194895A1 - 生体由来組織のシート、該シートから得られる管状構造体及び該管状構造体からなる人工血管 - Google Patents
生体由来組織のシート、該シートから得られる管状構造体及び該管状構造体からなる人工血管 Download PDFInfo
- Publication number
- WO2016194895A1 WO2016194895A1 PCT/JP2016/066003 JP2016066003W WO2016194895A1 WO 2016194895 A1 WO2016194895 A1 WO 2016194895A1 JP 2016066003 W JP2016066003 W JP 2016066003W WO 2016194895 A1 WO2016194895 A1 WO 2016194895A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sheet
- tubular structure
- tissue
- taper
- blood vessel
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3625—Vascular tissue, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0076—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof multilayered, e.g. laminated structures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0069—Three-dimensional shapes cylindrical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
Definitions
- the present invention relates to a living tissue-derived tissue sheet and a tubular structure obtained from the sheet, and also relates to a sheet and a tubular structure suitably used for artificial blood vessels and the like.
- Vascular grafts are used to construct blood vessels for bypass surgery and to repair or replace damaged or pathological blood vessels.
- autologous blood vessels are suitable replacement grafts for affected areas less than 5 mm in diameter, and the internal thoracic artery, radial artery, saphenous vein, etc. are used.
- invasiveness cannot be avoided at the time of collection, so that the burden on the patient's body is large, and variations in length and quality among individuals and cases are unavoidable.
- artificial blood vessels made of synthetic resin such as polyester fiber and polytetrafluoroethylene are used for revascularization of peripheral arteries.
- synthetic resin such as polyester fiber and polytetrafluoroethylene
- the lumen of the artificial blood vessel is coated with a patient's own vascular endothelial cell by a tissue engineering technique.
- bone marrow is collected from the patient, cultured, and engrafted in an artificial blood vessel. This is useful for surgery that requires prior preparation and must be performed in an emergency. Was low.
- the endothelial cells covering the lumen of the blood vessel are also easily peeled off, thereby causing a problem of thrombus formation.
- an artificial blood vessel has been proposed in which a sheet of biomaterial that has been decellularized to prevent rejection is formed into a tubular shape (Patent Document 1).
- This artificial blood vessel is formed by winding a sheet as it is in a tubular shape. For this reason, the edge of the sheet protrudes into the lumen of the tube by the thickness of the sheet in the cross section of the lumen, and the cross section of the tube does not become a circle or an ellipse (FIG. 8).
- the cross section of the tubular structure has such a shape, when blood flows, local pressure is applied to the protruding portion, which may cause peeling, and the pressure resistance of the blood vessel is not sufficient. It was.
- the present invention (1) The sheet
- Sheet of (3) The sheet of the biological tissue of (1) 1 or (2), wherein the taper angle is 10 ° or more and 80 ° or less, (4) The sheet of living tissue according to any one of (1) to (3), wherein the thickness of the sheet is 500 micrometers or less, (5) The sheet of living tissue according to any one of (1) to (4), wherein the taper has a shape in which only one edge of the sheet is inclined.
- the present invention it is possible to provide a living tissue-derived sheet for obtaining a tubular structure having excellent pressure resistance and handling properties. Since the taper portion has increased flexibility, the taper portion is firmly adhered and hardly peeled off or is difficult to squeeze. Therefore, the sheet of the present invention is excellent in workability. Moreover, the tubular structure which has the outstanding pressure
- a broken line 1 indicates the length direction of the sheet
- a broken line 2 indicates the width direction of the sheet
- a broken line 3 indicates the thickness direction of the sheet.
- a represents the taper angle
- b represents the thickness of the sheet
- c represents the tapered portion.
- (I) is the figure which showed a part (cross section of an edge part) of the sheet
- (Ii) is a figure showing the taper part formed in the edge part of the sheet
- the edge of only one side is inclined toward the end to form a taper.
- c corresponds to the tapered portion of FIG. More preferably, the ⁇ side (upper side) is a vascular intima tissue, and the ⁇ side (lower side) is a vascular intima tissue.
- a biological tissue sheet hereinafter also referred to as “sheet”
- tubular structure capable of suitably obtaining the tubular structure of the present invention
- the material of the sheet of the present invention is a living tissue (also referred to as “biological tissue”).
- derived from a living body refers to “derived from an animal”, preferably “derived from a vertebrate”, and more preferably, since there is little rejection reaction, “living tissue from mammals” or “living tissue derived from birds” ".
- living origin refers to a living tissue derived from a mammalian livestock, avian livestock or a human.
- Mammalian livestock includes cattle, horses, camels, llamas, donkeys, yaks, sheep, pigs, goats, deer, alpaca, dogs, raccoon dogs, weasels, foxes, cats, rabbits, hamsters, guinea pigs, rats, mice, squirrels, Raccoon etc. are mentioned.
- examples of avian livestock include parakeets, parrots, chickens, ducks, turkeys, geese, guinea fowls, pheasants, ostriches, and quails.
- bovine, pig, horse, and human biological tissues are preferable as materials, and pigs are more preferable from the viewpoint of easy availability and safety.
- a part having a matrix structure outside the cell can be used.
- a part having a matrix structure outside the cell examples include a liver, kidney, ureter, bladder, urethra, tongue, tonsils, esophagus, stomach, small intestine, Large intestine, anus, pancreas, heart, blood vessel, spleen, lung, brain, bone, spinal cord, cartilage, testis, uterus, fallopian tube, ovary, placenta, cornea, skeletal muscle, tendon, nerve, skin, fascia, pericardium, Examples include dura mater, umbilical cord, heart valve, cornea, amniotic membrane, intestinal tract, small intestine submucosa, and other collagen-containing tissues.
- vascular tissues such as arteries and veins are preferable from the viewpoint of ease of decellularization, availability, and pressure resistance and handling properties when formed into a tubular structure.
- a blood vessel tissue derived from an animal is preferable.
- the aorta, the carotid artery, the internal thoracic artery, the radial artery An artery such as the gastroepiploic artery is preferable, and an aorta having sufficient length and thickness and particularly excellent workability is more preferable.
- the vascular tissue is one or more of an intima tissue (hereinafter also referred to as “intima”), an intima tissue (hereinafter also referred to as “intima”), and an outer membrane tissue (hereinafter also referred to as “outer membrane”).
- intima an intima tissue
- intima an intima tissue
- outer membrane an outer membrane tissue
- outer membrane an outer membrane tissue
- a rectangle (rectangle) or a substantially rectangular shape is preferable from the point of the pressure
- the sheet is rectangular (rectangular) or substantially rectangular, its size may be appropriately selected depending on the size of the tubular structure to be produced, but from the viewpoint of pressure resistance and handling properties when it is a tubular structure,
- the length of one side in the length direction (also referred to as “long side”) is usually 10 to 400 millimeters, preferably 20 to 300 millimeters (for example, the broken line arrow 1 in FIG. 1 or FIG. 9).
- the length of one side in the width direction of the sheet is usually 1.5 to 200 millimeters, preferably 3.0 to 70 millimeters, and more preferably 6.0 to 40 millimeters. (For example, broken line arrow 2 in FIG. 1 or FIG. 9).
- the sheet of the present invention has a shape (taper) in which the edge of at least one side becomes thinner in the thickness direction toward the end. Typically, it has a shape like the part c of FIG. That is, both ends or one end of the cross section of the sheet are tapered. In this specification, such a shape is referred to as “taper”.
- the section of the sheet need not be processed linearly.
- a taper part may have in all the edge parts of 4 sides of a sheet, and the edge part of 3 sides, 2 sides, or 1 side of a sheet may be a taper shape.
- the sheet of the present invention is formed into a tubular structure by winding it in a tubular shape so that the tapered portion is inside the tube (on the lumen side when used as an artificial blood vessel).
- the number of production steps is smaller. Therefore, it is preferable to have a taper at the edge of at least two sides of the sheet, more preferably a taper at the edge of two sides in the length direction of the sheet, and a taper at the edge of one side of the sheet. Is still more preferable, and it is most preferable to have a taper at the edge of one side in the length direction.
- FIG. 1 represents a schematic view of one embodiment of a sheet derived from biological tissue before taper formation.
- Schematic diagrams of the taper at the edge of the sheet of the present invention are shown in FIGS. 2 to 5 are partial cross-sectional views in a direction perpendicular to the sheet length direction.
- a represents the taper angle (hereinafter referred to as “taper angle”)
- b represents the thickness of the sheet.
- the part represented by c is a taper part.
- FIG. 2 shows a part of a sectional view in a direction perpendicular to the length direction of FIG.
- FIG.2 and FIG.4 shows the state in which the edge of the single side
- FIG. 3 and FIG. 5 show a state in which the edges on both sides of the sheet are inclined to form a taper.
- the taper angle a is preferably 10 ° to 80 °, more preferably 15 ° to 70 °, and more preferably 20 ° to 65 °, from the viewpoint of pressure resistance and handling properties of the tubular structure when the sheet is formed into a tubular structure. Is more preferred, with 20 ° to 55 ° being most preferred.
- the sheet thickness b is preferably from 100 to 500 micrometers, more preferably from 150 to 400 micrometers, and even more preferably from 200 to 300 micrometers in terms of pressure resistance and handling properties when a tubular structure is formed. If the thickness of the sheet exceeds 500 micrometers, it may be too thick and difficult to process, and may be inappropriate when producing a small-diameter tubular structure.
- the sheet thickness b corresponds to the thickness of the sheet shown in FIGS. 1 and 9 (indicated by the dashed arrow 3).
- the shape of the taper is such that the cross section of the taper portion as shown in FIG. 2 or FIG. (Triangle, approximately isosceles triangle, etc.), and it is particularly preferable that the section of the taper as shown in FIG. 2 is a right triangle or a substantially right triangle.
- FIG. 2 shows that the inclination of the edge of one side of the sheet reaches the other side.
- the means for forming a taper at the edge of the sheet of the present invention can be any means, and is not particularly limited, but for example, cutting can be performed.
- a tool used for the cutting process a known tool can be used, and examples thereof include, but are not limited to, a cutter, a razor, a surgical knife, an ultrasonic cutter, and a microtome.
- the ratio with respect to the inner periphery when the tubular structure is formed is preferably 0.01 to 100%, more preferably 0.
- the taper portion is prepared so as to be 1 to 50%, more preferably 0.15 to 35%.
- the shape of the tapered portion of the sheet of the present invention is not particularly limited, and the cut surface after processing may be a flat surface or a curved surface, and may have a jagged shape such as unevenness or a saw blade in part. Considering the efficiency at the time of processing, it is desirable that all the cut surfaces after the cutting are flat.
- a sheet of biological tissue obtained from a blood vessel of an animal and decellularized is used.
- This bio-derived tissue sheet is mainly composed of a medial tissue and an intimal tissue.
- FIG. 6 (i) shows the biological tissue sheet of this preferred embodiment. With the broken line in this figure as the boundary, d represents the intima tissue and e represents the intima tissue. Then, in the case of a tubular structure, the cutting is preferably performed from the medial tissue side so that a tapered tip is formed at the bottom of the intimal tissue (FIG. 6 (ii)). .
- seat can be made thin, and also the cross section can give a taper in acute angle shape.
- the process of forming the taper on the sheet is preferably performed before winding the sheet into a tubular shape from the viewpoint of workability, but may be performed after being wound into a tubular shape.
- the biological tissue sheet of the present invention is preferably decellularized.
- the decellularization will be described in detail below.
- Decellularization is a process that removes highly antigenic components such as cells and nucleic acid components from tissues collected from animals, thereby suppressing rejection that occurs when used as a transplanted tissue to living bodies. can do.
- the decellularization method is not particularly limited, and a conventionally known method can be used.
- decellularization treatment include physical agitation, sonication, freeze-thaw method, high hydrostatic pressure method, hypertonic and hypotonic solution method, surface activity by anionic surfactants and nonionic masking agents, etc.
- Treatment with an agent, enzyme treatment with a proteolytic enzyme or nucleolytic enzyme, treatment with an alcohol solvent, etc. may be mentioned, and two or more of these may be combined.
- a method including a high hydrostatic pressure method is preferable from the viewpoint of blood compatibility because it can be efficiently decellularized while maintaining the mechanical strength of the structural protein.
- the decellularization treatment may be performed before forming the living tissue into a sheet, may be performed after forming the sheet shape, or may be performed after cutting to give a taper to the end of the sheet, or after that. Alternatively, it may be performed after forming the tubular structure. Preferably, from the viewpoint of processability and ease of decellularization, it is preferably performed before the tubular structure is formed, and more preferably after the biological tissue is formed into a sheet shape.
- the tubular structure of the present invention is formed using the living tissue-derived sheet of the present invention as a material. Specifically, the sheet of the present invention is obtained by winding the sheet into a tubular shape so that the tapered portion is located on the inner side (lumen side).
- FIG. 7 shows a preferred embodiment of the tubular structure of the present invention.
- the edge of the sheet protrudes into the lumen of the tube by the thickness direction of the sheet (FIG. 8).
- this tubular structure is used as an artificial blood vessel, when blood flows, local pressure is applied to the protruding portion, which may cause peeling, and the pressure resistance as an artificial blood vessel is sufficient. is not.
- the section of the tubular body is derived from the thickness of the edge of the sheet.
- the bulge disappears and the cross section of the tubular body becomes circular, elliptical, substantially circular, or substantially elliptical (for example, FIG. 7).
- pressure is uniformly applied to the inside of the tube, and the pressure resistance is excellent.
- the tubular structure has uniform flexibility and excellent handling properties. Further, since the pressure resistance is excellent, it is not necessary to increase the thickness of the sheet itself in order to obtain the pressure resistance, so that the handling property is excellent.
- a part of the wall part forming the tubular structure has a two-layer structure from the viewpoint of pressure resistance.
- a tubular structure body having a two-layer structure and a three-layer structure as the wall portion for example, FIG. 7 (i)
- a tubular structure having a two-layer structure as a whole and a tubular structure having a single-layer structure and a two-layer structure as walls for example, FIG. 7 (ii) are included.
- the distance on the outer wall from the point g on the outer wall to the point h clockwise in FIG. 7 (i) ) Is preferably 0% or more, more preferably 50% or more, and still more preferably 80% or more with respect to the length of the outer periphery.
- Point h is a point where a line extending perpendicularly from the tip of the tapered portion intersects the outer wall.
- the length of the outer periphery refers to the length of the outer wall portion of the tubular structure starting from an arbitrary point of the tubular structure.
- the length of the outer periphery in FIG. 7 (i) refers to the length of the outer wall portion of the tubular structure starting from g and ending.
- the length of the single-layer structure portion (the distance on the outer wall from the point j on the outer wall to the point k clockwise in FIG. 7 (ii)) ) Is preferably less than 100%, more preferably 50% or less, still more preferably 20% or less with respect to the length of the outer periphery.
- the point k is a point where the line extended perpendicularly
- the length of the outer periphery refers to the length of the outer wall portion of the tubular structure starting from an arbitrary point of the tubular structure.
- the length of the outer periphery in FIG. 7 (ii) refers to the length of the outer wall portion of the tubular structure starting from j and ending.
- tubular structure of the present invention is not limited to the tubular structure shown in FIG. 7, and a tubular structure having a wall portion of four or more layers is also included in the present invention.
- the front cross section of the tubular structure of the present invention is circular, substantially circular, elliptical or substantially elliptical as shown in FIGS. 7 (i) and (ii), and is flexible, so that the shape depends on the application. Can be deformed.
- the inner circumference is usually preferably from 1.5 to 200 millimeters, more preferably from 3.0 to 70 millimeters, still more preferably from 6.0 to 40 millimeters.
- the tubular structure of the present invention is produced from a living tissue-derived tissue sheet by, for example, a production method including the following steps (1) to (4).
- a production method including the following steps (1) to (4).
- the order of the steps (1) to (4) is not particularly limited, but from the viewpoint of ease of workability, (1), (2), (3), (4) or (1), (3), (2), (4) or (1), (3), (4), (2) or (2), (1), (3), preferably in the order of (4), (1) , (2), (3), (4) or (1), (3), (2), and (4) are more preferable.
- seat of the biological body tissue of this invention may be located inside a tubular body (lumen side).
- the sectional view of the taper is a right triangle or a substantially right triangle as shown in FIG. 2 and 9, either the ⁇ -side surface or the ⁇ -side surface can be the inner surface of the tubular structure, but the tube is wound so that the ⁇ -side surface becomes the inner surface of the tubular structure. It is preferable to form a structure.
- the sheet of the present invention is rectangular or substantially rectangular, from the viewpoint of workability, it is preferable to wind the tube so that the side in the length direction of the sheet is the length direction of the tubular structure.
- the tubular structure can be formed by winding a sheet around the core material.
- various core materials can be selected depending on the inner periphery and length of the target tubular structure, and the material is not limited. Since the outer periphery of the core material to be used generally corresponds to the inner periphery of the tubular structure, the core material may be appropriately selected according to the inner periphery of the target tubular structure.
- Examples of the core material include, but are not particularly limited to, tubes made of polytetrafluoroethylene (PTFE), polyurethane (PU), stainless steel (SUS), and columnar bars.
- PTFE polytetrafluoroethylene
- PU polyurethane
- SUS stainless steel
- the tubular structure of the present invention can be formed by stitching a part of a sheet or by bonding with an adhesive, and both of them may be used. From the viewpoint of processability, it is preferable to use an adhesive. Therefore, the taper portion of the sheet can be fixed to the inner wall of the tubular structure by means such as sewing or adhesive.
- the adhesive that can be used may be a conventionally used adhesive for living tissue, such as fibrin glue, cyanoacrylate polymerizable adhesive, gelatin glue that crosslinks gelatin and resorcinol with formalin, etc. From the viewpoint of properties, fibrin glue is preferred. Fibrin glue refers to a preparation that uses paste-like clots formed by the action of thrombin, an enzyme, on fibrinogen, for example for tissue closure, adhesion of organ damage, and hemostasis.
- the place where the adhesive is applied is not particularly limited as long as the sheet can be bonded so that the sheet forms a tubular structure. However, it is preferable to apply so that no adhesive is present on the inner wall surface of the tubular structure. This is because there is a possibility that the adhesive may have some adverse effects by coming into contact with a substance passing through the inside (lumen) of the tubular structure. Further, a sufficient adhesive is applied to the tapered portion so that the cross section of the tubular structure as shown in FIGS. 7 (i) and (ii) is circular, substantially circular, elliptical, or substantially elliptical. There is a need. This is because if the taper portion is insufficiently bonded, the pressure resistance of the portion may deteriorate, and a desired tubular structure cannot be obtained.
- a tubular structure can be prepared by applying an adhesive to the entire ⁇ -side surface of the sheet and bonding it to the ⁇ -side surface of the sheet. It is also possible to apply the adhesive only to the portion where the ⁇ -side surface of the sheet is bonded to the ⁇ -side surface, and bond them while winding them in a tubular shape. At this time, the adhesive is not applied to the portion that forms the outer wall surface of the tubular structure on the ⁇ -side surface of the sheet.
- the tubular structure of the present invention can be used as a graft for tubular living tissue.
- blood vessels, ureters, trachea, lymphatic vessels and the like can be mentioned, and the use for artificial blood vessels is particularly preferable.
- the tubular structure of the present invention is excellent in pressure resistance. Particularly when used for an artificial blood vessel, the pressure resistance is preferably 300 mmHg or more, more preferably 400 mmHg or more. Moreover, the tubular structure of the present invention is excellent in handling properties during surgery and the like.
- Example 1 Tubular structure No. Preparation of 1] ⁇ Sheet molding process, decellularization process> Porcine aorta was purchased from the slaughterhouse and transported at 4 ° C. The aorta outer membrane was totally peeled and removed, and then cut open. The incised aorta was cut into a substantially rectangular shape with a length of 170 mm and a width of 27 mm. The obtained sheet was subjected to high hydrostatic pressure treatment at 100 MPa for 15 minutes using a high-pressure treatment apparatus for research and development (manufactured by Kobe Steel, Ltd .: Dr.
- ⁇ Tip processing step> The film thickness of the decellularized porcine aortic sheet obtained above was 258 micrometers.
- the edge of one side in the length direction of this sheet is cut with a blade (made by Feather Safety Razor Co., Ltd., model number: SH35W) while adjusting the incident angle of the blade from the medial tissue side to the medial tissue side. And it cut so that the cross section of the edge part of a sheet
- the obtained tubular structure No. 1 is cut in a direction perpendicular to the length direction, the cut surface is observed, and the taper angle of a cut end (taper portion, hereinafter also referred to as “cut end”), which is the beginning of winding of the tube, and The length of the tapered portion was measured with an inverted microscope for research (Nikon Corporation, model number: ECLIPSE Ti). The results are shown in Table 1. Moreover, the pressure resistance test was done by the following ⁇ pressure resistance test method> using the obtained tubular structure. The results are shown in Table 1. Moreover, the handling property test was done by the following ⁇ handling test method> using the obtained tubular structure. The results are shown in Table 1.
- Example 2 Tubular structure No. Preparation of 2 This procedure was the same as in Example 1 except that the thickness of the decellularized porcine aortic sheet was 217 micrometers and that the taper angle was changed and the taper angle was changed when forming the tapered portion.
- the tubular structure No. 1 of the invention. 2 was obtained.
- the obtained tubular structure No. The taper angle of 2 was measured in the same manner as in Example 1, and further a pressure resistance test and a handling property test were performed. The results are shown in Table 1.
- Example 3 Tubular structure No. Production of 3 This procedure is the same as in Example 1 except that the thickness of the decellularized porcine aortic sheet is 275 micrometers and the taper angle is changed by changing the incident angle of the blade when forming the tapered portion.
- the tubular structure No. 1 of the invention. 3 obtained.
- the obtained tubular structure No. A taper angle of 3 was measured in the same manner as in Example 1, and further a pressure resistance test and a handling property test were performed. The results are shown in Table 1.
- Example 4 Tubular structure No. Preparation of 4 This procedure is the same as in Example 1 except that the thickness of the decellularized porcine aortic sheet is 173 micrometers and the taper angle is changed by adjusting the incident angle of the blade during edge processing.
- the tubular structure No. 1 of the invention. 4 was obtained.
- the obtained tubular structure No. A taper angle of 4 was measured in the same manner as in Example 1, and a pressure resistance test and a handling property test were further performed.
- the results are shown in Table 1.
- Example 5 Tubular structure No. Preparation of 5] This procedure is the same as in Example 1 except that the thickness of the decellularized porcine aortic sheet is 276 micrometers and that the taper angle is changed and the taper angle is changed when the taper portion is formed.
- the tubular structure No. 1 of the invention. 5 was obtained.
- the obtained tubular structure No. A taper angle of 5 was measured in the same manner as in Example 1, and a pressure resistance test and a handling property test were
- Example 6 Tubular structure No. Preparation of 6 This procedure is the same as in Example 1 except that the thickness of the decellularized porcine aorta sheet is 291 micrometers and the taper angle is changed by changing the incident angle of the blade when forming the tapered portion.
- the tubular structure No. 1 of the invention. 6 was obtained.
- the obtained tubular structure No. The taper angle of 6 was measured in the same manner as in Example 1, and further a pressure resistance test and a handling property test were performed. The results are shown in Table 1.
- Example 7 Tubular structure No. 7 This procedure is the same as in Example 1 except that the thickness of the decellularized porcine aortic sheet is 202 micrometers and that the taper angle is changed and the taper angle is changed when forming the tapered portion.
- the tubular structure No. 1 of the invention. 7 was obtained.
- the obtained tubular structure No. A taper angle of 7 was measured in the same manner as in Example 1, and further a pressure resistance test and a handling property test were performed. The results are shown in Table 1.
- Example 8 Tubular structure No. 8 production This procedure is the same as in Example 1 except that the thickness of the decellularized porcine aortic sheet is 660 micrometers and that the taper angle is changed and the taper angle is changed when forming the tapered portion.
- the tubular structure No. 1 of the invention. 8 was obtained.
- the obtained tubular structure No. A taper angle of 8 was measured in the same manner as in Example 1, and a pressure resistance test and a handling property test were further performed. The results are shown in Table 1.
- Example 1 Comparative tubular structure No. Production of C1
- a decellularization step was performed in the same manner as in Example 1 to obtain a decellularized porcine aorta sheet.
- the obtained decellularized porcine aorta sheet was cut into a substantially rectangular shape having a length of 170 mm and a width of 27 mm.
- the sheet thickness was 255 micrometers.
- Comparative Example 2 Comparative tubular structure No. C2
- a decellularization step was performed in the same manner as in Example 1 to obtain a decellularized porcine aorta sheet.
- the obtained decellularized porcine aorta sheet was cut into a substantially rectangular shape having a length of 170 mm and a width of 27 mm.
- the film thickness of the sheet was 600 micrometers.
- cutting is performed with a blade from the medial tissue side to the intimal tissue side, and the shape of the cutting surface intersects perpendicularly with the bottom surface of the sheet It processed so that it might become a substantially rectangular shape.
- An attempt was made to produce C2, but a tubular structure could not be obtained. Since the sheet thickness was large and it was not tapered, it could not be tubular.
- ⁇ Pressure resistance test method> A syringe pump (YSP-101, YMC Co., Ltd.) was connected to one end of the obtained tubular structure via a silicon tube, and the other end was closed by connecting a pressure gauge. Saline was sent out from the syringe and maintained for 30 seconds each time the pressure was increased by 10 mmHg to observe whether there was any leakage or breakage of the saline from the tube. The pressure was increased, and the pressure immediately before the physiological saline leak or breakage was confirmed was taken as the pressure resistance of the tube. It can be said that the higher the pressure, the better the pressure resistance.
- No. 7 is particularly excellent in pressure resistance and handling properties. Therefore, it can withstand the blood pressure required when the tubular structure of the present invention is used for an artificial blood vessel. From the viewpoint of handling properties, it is easy to perform an artificial blood vessel transplantation operation.
- No. No. 8 also had excellent pressure resistance and handling properties.
- the comparative tubular structure No. C1 was found to have good handleability but poor pressure resistance. No. of the comparative tubular structure. Since C2 had a large film thickness and was not tapered, a tubular structure could not be obtained.
- broken line arrow 1 sheet length direction
- broken line arrow 2 sheet width direction
- broken line arrow 3 sheet thickness direction
- a taper angle
- b sheet thickness
- c taper part
- d medial structure
- e inner membrane structure
- f length of tapered portion
- g end point of two-layer structure portion
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
Description
たとえば冠状動脈や末梢血管のアテローム硬化症に対して、直径5mm未満の患部には、自己血管が好適な置換移植片であり、自己の内胸動脈、橈骨動脈、伏在静脈などが用いられている。しかしながら、自己の血管を使用する場合、採取時に侵襲を避けることはできないため、患者の身体への負担が大きく、また個人や症例により、その長さや質にばらつきがあることは避けられない。さらには再手術の場合には、既に使用されていて供給できない等の問題があった。
すなわち本発明は、
(1)少なくとも1辺の縁部が末端に向かって厚み方向に薄くなるテーパーを有する、生体由来組織のシート、
(2)前記生体由来組織のシートは、矩形又は略矩形であって、長さ方向の少なくとも1辺の縁部が末端に向かって厚み方向に薄くなるテーパーを有する、(1)の生体由来組織のシート、
(3)前記テーパーの角度が、10°以上、80°以下である、(1)1又は(2)の生体由来組織のシート、
(4)前記シートの厚みが、500マイクロメートル以下である、(1)~(3)の何れかの生体由来組織のシート、
(5)前記テーパーは前記シートの片面の縁部のみが傾斜した形状である、(1)~(4)の何れかの生体由来組織のシート、
(6)前記生体由来組織が動物の血管である、(1)~(5)の何れかの生体由来組織のシート、
(7)前記生体由来組織のシートが、脱細胞化された組織である(1)~(6)の何れかの生体由来組織のシート、
(8)(1)~(7)の何れかの生体由来組織のシートのテーパー部が内側に位置し、かつ内壁に固定化されている、管状構造体、
(9)(1)~(6)の何れかの生体由来組織のシートのテーパー部が内側に位置するように管状に巻いて内壁に固定化された後、脱細胞化されて得られる、管状構造体、
(10)管状構造体の壁部の少なくとも一部が2層構造である、(8)又は(9)に記載の管状構造体、
(11)前記テーパー部が接着され内壁に固定化されている、(8)~(10)の何れかの管状構造体、
(12)前記管状構造体の内周が、6.0ミリメートル以上、40ミリメートル以下である、(8)~(11)の何れかの管状構造体、
(13)(8)~(12)の何れかの管状構造体から得られる人工血管、
(14)(8)~(12)の何れかの管状構造体を人工血管として使用する方法、及び
(15)人工血管の製造における、(8)~(12)の何れか1項に記載された管状構造体の使用を提供する。
これらの中でも、脱細胞化のし易さや、入手のし易さ、管状構造体にしたときの耐圧性とハンドリング性の点から、動脈や静脈などの血管組織が好ましい。
また、内膜組織と中膜組織から構成される血管組織を使用する場合、管の内側が内膜組織となるように、管状構造を形成することが好ましい。
同様に、シートの幅方向の1辺の長さ(「短辺」とも称す)は通常1.5~200ミリメートルであり、3.0~70ミリメートルが好ましく、6.0~40ミリメートルがより好ましい(例えば、図1又は図9の破線矢印2)。
本発明のシートの縁部のテーパーの概略図を図2~図5に示す。図2~図5は、シートの長さ方向に対して垂直な方向の断面図の一部である。aはテーパーの角度(以下、「テーパー角」と称する)を表し、bはシートの厚さを表す。cで表された部分がテーパー部である。図2は、図1の長さ方向に対して垂直な方向の断面図の一部を示す。
ここで、図2及び図4はシートの片面の縁部が傾斜してテーパーが形成されている状態を示す。さらに、図3及び図5はシートの両面の縁部が傾斜してテーパーが形成されている状態を示す。
なお、ここでのシート厚さbは、図1及び図9のシートの厚さ(破線矢印3で示される)と対応する。
また、シートにテーパーを形成する加工は、シートを管状に巻く前に行っておくのが、加工性の点から好ましいが、管状に巻いてから行ってもよい。
脱細胞化とは、動物から採取した組織から細胞および核酸成分などの抗原性の高い成分を除去する処理を行うことであり、これにより生体への移植組織として使用した場合に起こる拒絶反応を抑制することができる。
シートの縁部にテーパーを設けないで管状構造体を形成すると、シートの縁部がシートの厚み方向の分だけ管の内腔に突き出た状態となる(図8)。例えば、この管状構造体を人工血管として使用した場合、血液が流れたときに、その突き出た部分に局所的な圧力がかかり、それによりはがれが生じる場合があり、人工血管としての耐圧性が充分ではない。
また耐圧性に優れるため、耐圧性を出すために、シート自体の厚さを厚くせずに済むので、ハンドリング性に優れることになる。
なお、点hはテーパー部の先端部から垂直に伸びた線が外壁部に交わる点である。
また、外周の長さは、管状構造体の任意の1点を始点及び終点とする管状構造体の外壁部の長さを指す。例えば、図7(i)の外周の長さとは、gを始点及び終点とする管状構造体の外壁部の長さを指す。
なお、点kはテーパー部の先端部から垂直に伸びた線が外壁部に交わる点である。
また、外周の長さは、管状構造体の任意の1点を始点及び終点とする管状構造体の外壁部の長さを指す。例えば、図7(ii)の外周の長さとは、jを始点及び終点とする管状構造体の外壁部の長さを指す。
本発明の管状構造体は、生体由来組織のシートから、例えば、以下の(1)から(4)の工程を含む製造方法によって作製される。
(1)生体由来組織をシート形状に成形する工程
(2)生体由来組織の脱細胞化処理工程
(3)シートの少なくとも1辺の縁部を薄く切削加工し、テーパーを付与する縁部を加工する工程
(4)シートを巻いて管状構造を形成する工程
そして、図2、図9におけるα側の面かβ側の面のいずれも管状構造体の内側面となり得るが、β側の面を管状構造体の内側面となるように管を巻いて管状構造体を形成することが好ましい。
また本発明の管状構造体は、手術時等のハンドリング性に優れる。
〔実施例1 管状構造体No.1の作製〕
<シート成形工程、脱細胞化工程>
屠畜場からブタ大動脈を購入し、4℃にて搬送した。この大動脈の外膜を全体的に剥離し除去した後、切り開いた。切開した大動脈を、長さ170ミリメートル、幅27ミリメートルの略矩形状に切り出した。得られたシートを、生理食塩水を媒体として、研究開発用高圧処理装置((株)神戸製鋼所製:Dr.CHEF)で100MPaにて15分間高静水圧処理を行った。処理したシートを核酸分解酵素のDNaseを20ppm含有する生理食塩水中、4℃で96時間振盪し、続いて80%エタノール中で4℃にて72時間、最後に生理食塩水中で4℃にて2時間洗浄を行って脱細胞化ブタ大動脈シートを得た。
上記で得られた、脱細胞化ブタ大動脈シートの膜厚は258マイクロメートルであった。このシートの長さ方向の一辺の縁部について、刃の入射角を調整しながら、中膜組織側から内膜組織側に向かって、ブレード(フェザー安全剃刀株式会社製、型番:SH35W)で切削して、シートの縁部の断面が図6(ii)のような形状を有するように切削加工した。
切削加工して得られた、加工シートの内膜組織が管状構造体に成形後内側になるようにして、生体接着剤のフィブリン糊を、切削面と中膜組織側の面に塗布しながら、外径3.0ミリメートルのPTFEチューブを芯として巻きつけ、5分間圧着して成形した。それを生理食塩水に浸漬し、芯材のPTFEチューブを抜き取り、長さ120ミリメートルとなるように両端を切断して、本発明の管状構造体No.1を作製した。
また、得られた管状構造体を用いて、下記<耐圧試験方法>で、耐圧性の試験を行った。結果を表1に示す。
また、得られた管状構造体を用いて、下記<ハンドリング試験方法>で、ハンドリング性の試験を行った。結果を表1に示す。
脱細胞化ブタ大動脈シートの膜厚が、217マイクロメートルであることと、テーパー部形成時に、ブレードの入射角を調整し、テーパー角を変えた以外は、実施例1と同様の手順で、本発明の管状構造体No.2を得た。得られた管状構造体No.2のテーパー角を実施例1と同様に測定し、さらに耐圧性の試験とハンドリング性の試験を行った。結果を表1に示す。
脱細胞化ブタ大動脈シートの膜厚が、275マイクロメートルであることと、テーパー部形成時に、ブレードの入射角を調整し、テーパー角を変えた以外は、実施例1と同様の手順で、本発明の管状構造体No.3得た。得られた管状構造体No.3のテーパー角を実施例1と同様に測定し、さらに耐圧性の試験とハンドリング性の試験を行った。結果を表1に示す。
脱細胞化ブタ大動脈シートの膜厚が、173マイクロメートルであることと、縁部加工時に、ブレードの入射角を調整し、テーパー角を変えた以外は、実施例1と同様の手順で、本発明の管状構造体No.4を得た。得られた管状構造体No.4のテーパー角を実施例1と同様に測定し、さらに耐圧性の試験とハンドリング性の試験を行った。結果を表1に示す。
〔実施例5 管状構造体No.5の作製〕
脱細胞化ブタ大動脈シートの膜厚が、276マイクロメートルであることと、テーパー部形成時に、ブレードの入射角を調整し、テーパー角を変えた以外は、実施例1と同様の手順で、本発明の管状構造体No.5を得た。得られた管状構造体No.5のテーパー角を実施例1と同様に測定し、さらに耐圧性の試験とハンドリング性の試験を行った。結果を表1に示す。
脱細胞化ブタ大動脈シートの膜厚が、291マイクロメートルであることと、テーパー部形成時に、ブレードの入射角を調整し、テーパー角を変えた以外は、実施例1と同様の手順で、本発明の管状構造体No.6を得た。得られた管状構造体No.6のテーパー角を実施例1と同様に測定し、さらに耐圧性の試験とハンドリング性の試験を行った。結果を表1に示す。
脱細胞化ブタ大動脈シートの膜厚が、202マイクロメートルであることと、テーパー部形成時に、ブレードの入射角を調整し、テーパー角を変えた以外は、実施例1と同様の手順で、本発明の管状構造体No.7を得た。得られた管状構造体No.7のテーパー角を実施例1と同様に測定し、さらに耐圧性の試験とハンドリング性の試験を行った。結果を表1に示す。
脱細胞化ブタ大動脈シートの膜厚が、660マイクロメートルであることと、テーパー部形成時に、ブレードの入射角を調整し、テーパー角を変えた以外は、実施例1と同様の手順で、本発明の管状構造体No.8を得た。得られた管状構造体No.8のテーパー角を実施例1と同様に測定し、さらに耐圧性の試験とハンドリング性の試験を行った。結果を表1に示す。
ブタ大動脈を用いて、実施例1と同様に脱細胞化工程を行い、脱細胞化ブタ大動脈シートを得た。
得られた脱細胞化ブタ大動脈シートを長さ170ミリメートル、幅27ミリメートルの略矩形状に切り出した。シートの膜厚は255マイクロメートルであった。
ブタ大動脈を用いて、実施例1と同様に脱細胞化工程を行い、脱細胞化ブタ大動脈シートを得た。
得られた脱細胞化ブタ大動脈シートを長さ170ミリメートル、幅27ミリメートルの略矩形状に切り出した。シートの膜厚は600マイクロメートルであった。
このシートの長さ方向の一辺について、刃の入射角を調整しながら、中膜組織側から内膜組織側に向かって、ブレードで切削して、切削面の形状がシートの底面に垂直に交わる略矩形となるように加工した。それ以外は実施例1と同様にして、比較管状構造体No.C2の作製を試みたが、管状構造体を得ることができなかった。シート膜厚が厚く、かつテーパー加工されていなかったため、管状化することができなかった。
得られた管状構造体の一端にシリコンチューブを介してシリンジポンプ((株)ワイエムシィ社製YSP-101)を接続し、もう一方の端は圧力計を接続して閉塞させた。シリンジから生理食塩水を送り出し、圧力を10mmHg増やすごとに30秒間その状態を保ち、チューブからの生理食塩水の漏れや破損がないかを観察した。圧力を増加させてゆき、生理食塩水の漏れや破損が確認された直前の圧力をそのチューブの耐圧性とした。圧力が高いほど耐圧性に優れるといえる。
得られた管状構造体について両端をピンセットで挟み、この管状構造体の中心部を支点にして、この両端を接触させるように180℃に折り曲げる試行をそれぞれの管状構造体について50回行い、試行後の管状構造体の状態を観察した。試行前と管状構造体の状態が変わらないものを良好、接着が剥がれたり、開口部にほつれが生じたりして管状構造体が破損したものを不良として評価した。また、わずかに接着部に剥がれが認められたり、わずかに開口部にほつれが生じたりしたものを、その中間の評価として、可と評価した。
これに対し、比較管状構造体のNo.C1はハンドリング性は可だが、耐圧性に劣ることがわかった。比較管状構造体のNo.C2は、膜厚が厚くかつテーパー加工されていなかったため、管状構造体を得ることができなかった。
a:テーパー角、b:シートの厚み、c:テーパー部、d:中膜組織、e:内膜組織、f:テーパー部の長さ、g、h:2層構造部の端点、j、k:単層構造部の端点
Claims (15)
- 少なくとも1辺の縁部が末端に向かって厚み方向に薄くなるテーパーを有する、生体由来組織のシート。
- 前記生体由来組織のシートは、矩形又は略矩形であって、長さ方向の少なくとも1辺の縁部が末端に向かって厚み方向に薄くなるテーパーを有する、請求項1に記載の生体由来組織のシート。
- 前記テーパーの角度が、10°以上、80°以下である、請求項1又は2に記載の生体由来組織のシート。
- 前記シートの厚みが、500マイクロメートル以下である、請求項1~3の何れか1項に記載の生体由来組織のシート。
- 前記テーパーは前記シートの片面の縁部が傾斜した形状である、請求項1~4の何れか1項に記載の生体由来組織のシート。
- 前記生体由来組織が動物の血管である、請求項1~5の何れか1項に記載の生体由来組織のシート。
- 前記生体由来組織のシートが、脱細胞化された組織である請求項1~6の何れかに記載の生体由来組織のシート。
- 請求項1~7の何れか1項に記載の生体由来組織のシートのテーパー部が内側に位置し、かつ内壁に固定化されている、管状構造体。
- 請求項1~6の何れか1項に記載の生体由来組織のシートのテーパー部が内側に位置するように管状に巻いて内壁に固定化された後、脱細胞化されて得られる、管状構造体。
- 管状構造体の壁部の少なくとも一部が2層構造である、請求項8又は9に記載の管状構造体。
- 前記縁部が接着され内壁に固定化されている、請求項8~10の何れか1項に記載の管状構造体。
- 前記管状構造体の内周が、6.0ミリメートル以上、40ミリメートル以下である、請求項8~11の何れか1項に記載の管状構造体。
- 請求項8~12の何れか1項に記載された管状構造体からなる人工血管。
- 請求項8~12の何れか1項に記載された管状構造体を人工血管として使用する方法。
- 人工血管の製造における、請求項8~12の何れか1項に記載された管状構造体の使用。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/576,761 US20180296728A1 (en) | 2015-06-02 | 2016-05-31 | Sheet of biological tissue, tubular structure obtained from said sheet, and artificial blood vessel comprising said tubular structure |
CN201680032458.2A CN107708612B (zh) | 2015-06-02 | 2016-05-31 | 源自生物体的组织的片材、由该片材得到的管状结构体以及包含该管状结构体的人工血管 |
CA2987723A CA2987723C (en) | 2015-06-02 | 2016-05-31 | Sheet of biological tissue, tubular structure obtained from said sheet, and artificial blood vessel comprising said tubular structure |
KR1020177035885A KR102659840B1 (ko) | 2015-06-02 | 2016-05-31 | 생체 유래 조직의 시트, 상기 시트에서 얻은 관상 구조체 및 상기 관상 구조체로 이루어진 인공 혈관 |
EP16803329.8A EP3305248A4 (en) | 2015-06-02 | 2016-05-31 | BIOLOGICAL TISSUE SHEET, TUBULAR STRUCTURE PRODUCED THEREFROM, AND ARTIFICIAL BLOOD VESSEL COMPRISING THE TUBULAR STRUCTURE |
JP2017521947A JP6745264B2 (ja) | 2015-06-02 | 2016-05-31 | 生体由来組織のシート、該シートから得られる管状構造体及び該管状構造体からなる人工血管 |
HK18106721.3A HK1247077A1 (zh) | 2015-06-02 | 2018-05-24 | 源自生物體的組織的片材、由該片材得到的管狀結構體以及包含該管狀結構體的人工血管 |
US17/851,283 US20220323647A1 (en) | 2015-06-02 | 2022-06-28 | Sheet of biological tissue, tubular structure obtained from said sheet, and artificial blood vessel comprising said tubular structure |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-111957 | 2015-06-02 | ||
JP2015111957 | 2015-06-02 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/576,761 A-371-Of-International US20180296728A1 (en) | 2015-06-02 | 2016-05-31 | Sheet of biological tissue, tubular structure obtained from said sheet, and artificial blood vessel comprising said tubular structure |
US17/851,283 Division US20220323647A1 (en) | 2015-06-02 | 2022-06-28 | Sheet of biological tissue, tubular structure obtained from said sheet, and artificial blood vessel comprising said tubular structure |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016194895A1 true WO2016194895A1 (ja) | 2016-12-08 |
Family
ID=57440452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/066003 WO2016194895A1 (ja) | 2015-06-02 | 2016-05-31 | 生体由来組織のシート、該シートから得られる管状構造体及び該管状構造体からなる人工血管 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20180296728A1 (ja) |
EP (1) | EP3305248A4 (ja) |
JP (2) | JP6745264B2 (ja) |
KR (1) | KR102659840B1 (ja) |
CN (1) | CN107708612B (ja) |
CA (1) | CA2987723C (ja) |
HK (1) | HK1247077A1 (ja) |
TW (1) | TWI720988B (ja) |
WO (1) | WO2016194895A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018221402A1 (ja) * | 2017-05-30 | 2018-12-06 | 哲哉 樋上 | 移植用脱細胞化材料の製造方法及び当該材料を含む生体適合性材料からなる移植片組成物 |
WO2019087880A1 (ja) | 2017-10-31 | 2019-05-09 | 株式会社Adeka | シート状脱細胞化材料及び同材料を用いる人工血管 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09508563A (ja) * | 1995-02-28 | 1997-09-02 | フォトジェネシス インコーポレイテッド | 平らな移植片を用意し且つ移植する方法及びこのための手術装置 |
JP2009254777A (ja) * | 2007-07-19 | 2009-11-05 | National Cardiovascular Center | 人工血管又は血液通管の接続ユニット及び接続構造 |
JP2013503696A (ja) * | 2009-09-02 | 2013-02-04 | ライフセル コーポレーション | 無細胞性組織マトリックスに由来する血管移植片 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3588920A (en) * | 1969-09-05 | 1971-06-29 | Sigmund A Wesolowski | Surgical vascular prostheses formed of polyester fiber paper |
US5865723A (en) * | 1995-12-29 | 1999-02-02 | Ramus Medical Technologies | Method and apparatus for forming vascular prostheses |
US6127597A (en) | 1997-03-07 | 2000-10-03 | Discotech N.V. | Systems for percutaneous bone and spinal stabilization, fixation and repair |
US6737053B1 (en) * | 1999-11-12 | 2004-05-18 | National University Of Singapore | Tissue-engineered ligament |
DE10060443A1 (de) * | 2000-11-29 | 2002-06-06 | Biotronik Mess & Therapieg | Stent aus menschlichem oder tierischem Gewebe |
WO2006056981A1 (en) * | 2004-11-24 | 2006-06-01 | Joel Ovil | Stent with ratchet-mechanism |
WO2006099016A2 (en) | 2005-03-09 | 2006-09-21 | Providence Health System | A composite multi-layered vascular graft prosthesis |
US20080071346A1 (en) * | 2006-09-14 | 2008-03-20 | Boston Scientific Scimed, Inc. | Multilayer Sheet Stent |
AU2008363361A1 (en) | 2007-10-03 | 2010-06-10 | The General Hospital Corporation | Photochemical tissue bonding |
CA2785989A1 (en) * | 2009-12-31 | 2011-07-07 | Neograft Technologies, Inc. | Graft devices and methods of fabrication |
WO2013070670A1 (en) | 2011-11-10 | 2013-05-16 | Lifecell Corporation | Device for tendon and ligament treatment |
CN103977457A (zh) * | 2014-05-30 | 2014-08-13 | 国家纳米科学中心 | 一种管状组织工程支架及其制备方法 |
-
2016
- 2016-05-31 WO PCT/JP2016/066003 patent/WO2016194895A1/ja active Application Filing
- 2016-05-31 JP JP2017521947A patent/JP6745264B2/ja active Active
- 2016-05-31 US US15/576,761 patent/US20180296728A1/en not_active Abandoned
- 2016-05-31 CN CN201680032458.2A patent/CN107708612B/zh active Active
- 2016-05-31 EP EP16803329.8A patent/EP3305248A4/en active Pending
- 2016-05-31 CA CA2987723A patent/CA2987723C/en active Active
- 2016-05-31 KR KR1020177035885A patent/KR102659840B1/ko active IP Right Grant
- 2016-06-02 TW TW105117388A patent/TWI720988B/zh active
-
2018
- 2018-05-24 HK HK18106721.3A patent/HK1247077A1/zh unknown
-
2020
- 2020-08-03 JP JP2020131507A patent/JP7026175B2/ja active Active
-
2022
- 2022-06-28 US US17/851,283 patent/US20220323647A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09508563A (ja) * | 1995-02-28 | 1997-09-02 | フォトジェネシス インコーポレイテッド | 平らな移植片を用意し且つ移植する方法及びこのための手術装置 |
JP2009254777A (ja) * | 2007-07-19 | 2009-11-05 | National Cardiovascular Center | 人工血管又は血液通管の接続ユニット及び接続構造 |
JP2013503696A (ja) * | 2009-09-02 | 2013-02-04 | ライフセル コーポレーション | 無細胞性組織マトリックスに由来する血管移植片 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018221402A1 (ja) * | 2017-05-30 | 2018-12-06 | 哲哉 樋上 | 移植用脱細胞化材料の製造方法及び当該材料を含む生体適合性材料からなる移植片組成物 |
JPWO2018221402A1 (ja) * | 2017-05-30 | 2020-04-30 | 株式会社Adeka | 移植用脱細胞化材料の製造方法及び当該材料を含む生体適合性材料からなる移植片組成物 |
WO2019087880A1 (ja) | 2017-10-31 | 2019-05-09 | 株式会社Adeka | シート状脱細胞化材料及び同材料を用いる人工血管 |
EP3705141A4 (en) * | 2017-10-31 | 2021-08-18 | Adeka Corporation | LEAF-SHAPED DECELLULARIZED MATERIAL AND ARTIFICIAL BLOOD VESSEL WITH USE OF THE SAID MATERIAL |
AU2018358273B2 (en) * | 2017-10-31 | 2023-11-16 | Adeka Corporation | Sheet-like decellularized material and artificial blood vessel employing said material |
Also Published As
Publication number | Publication date |
---|---|
TW201711644A (zh) | 2017-04-01 |
US20180296728A1 (en) | 2018-10-18 |
EP3305248A1 (en) | 2018-04-11 |
CN107708612A (zh) | 2018-02-16 |
JP6745264B2 (ja) | 2020-08-26 |
US20220323647A1 (en) | 2022-10-13 |
TWI720988B (zh) | 2021-03-11 |
EP3305248A4 (en) | 2019-02-13 |
JP7026175B2 (ja) | 2022-02-25 |
CN107708612B (zh) | 2020-12-29 |
KR20180015156A (ko) | 2018-02-12 |
KR102659840B1 (ko) | 2024-04-22 |
CA2987723A1 (en) | 2016-12-08 |
JP2020185432A (ja) | 2020-11-19 |
CA2987723C (en) | 2023-09-19 |
HK1247077A1 (zh) | 2018-09-21 |
JPWO2016194895A1 (ja) | 2018-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220323647A1 (en) | Sheet of biological tissue, tubular structure obtained from said sheet, and artificial blood vessel comprising said tubular structure | |
AU2013373262B2 (en) | Artificial blood vessel using decellularized blood vessel sheet | |
US10987449B2 (en) | Decellularization method and system and decellularized tissue formed thereby | |
JP2023076668A (ja) | 移植用脱細胞化材料の製造方法及び当該材料を含む生体適合性材料からなる移植片組成物 | |
JP2011025002A (ja) | 弁付人工血管及び弁付人工血管用柱状芯基材並びに弁付人工血管の製造方法 | |
JP7412174B2 (ja) | シート状脱細胞化材料及び同材料を用いる人工血管 | |
WO2021006335A1 (ja) | 結合組織体及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16803329 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017521947 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15576761 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2987723 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20177035885 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016803329 Country of ref document: EP |